Press releases
Half-year report July 1 – December 31, 2024
27 February, 2025By “Company” or “DexTech” is meant DexTech Medical AB with organization number 556664-6203. Summary of the second quarter (2024-10-01 – 2024-12-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss […]
DexTech Medical is funded through Q4, 2026
25 February, 2025Regarding the ongoing Phase 1 study investigating the efficacy of OsteoDex in patients with progressive treatment-resistant multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond […]
Bulletin from the Annual General Meeting
31 October, 2024Today, October 31, 2024, the Annual General Meeting of DexTech Medical AB was held. All resolutions were passed with the required majority. Resolution on adoption of the income statement and […]
Interim report July 1- September 30, 2024
24 October, 2024Summary of the first quarter (2024-07-01 – 2024-09-30) • Net sales amounted to MSEK 0,0 (0,0) • Operating profit/loss amounted to MSEK -1,3 (-1,1) • Earnings per share* SEK -0.06 […]
DexTech: Invitation to open Annual General Meeting and notice
26 September, 2024On Thursday, October 31, 2024, DexTech Medical AB (“DexTech”) will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, […]
Dextech Medical AB Annual report 230701-240630
20 September, 2024Download the annual report below. Annual report DexTech Medical AB 230701-240630
Year-end report July 1, 2023 – June 30, 2024
30 August, 2024Summary of year-end report Fourth quarter (2024-04-01 – 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6 million (-1.3) Earnings per share* SEK -0.07 […]
DexTech Medical announces continued positive results from myeloma study
12 August, 2024The Phase 1 study examines the effect of OsteoDex on patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. […]
Interim report July 1, 2023 – March 31, 2024
26 April, 2024Summary of the third quarter (2024-01-01 – 2024-03-31) Net sales amounted to MSEK 0,0 (0,0) Operating profit/loss amounted to MSEK -1,5 (-1,6) Earnings per share* SEK -0.08 (-0.08) Summary of […]
DexTech Medical announces new positive results from the myeloma study
15 April, 2024The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). Progressive disease means that the disease progresses and does not respond to existing treatment. […]